---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-068020"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:44:51.838425+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q1 net loss narrows to $9.1M; ATH-1105 Phase 1 complete, ALS dosing on track

## Summary
- Cash, cash equivalents and investments totaled $36.7M as of March 31, 2025, down from $51.3M at year-end 2024.
- Net loss for Q1 2025 was $9.1M ($0.23 per share) vs $26.3M ($0.69 per share) in Q1 2024.
- R&D expenses fell to $4.3M from $21.2M, driven by fosgonimeton program cuts after failed LIFT-AD trial.
- ATH-1105 Phase 1 healthy volunteer study completed; full data expected 2H25, ALS patient dosing to begin late 2025.
- Company exploring strategic alternatives with Cantor Fitzgerald after discontinuing fosgonimeton development.

## SEC filing metadata
- accession: 0000950170-25-068020
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017025068020/0000950170-25-068020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017025068020/atha-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-068020
- JSON: https://secwatch.observer/filing/0000950170-25-068020.json
- Plain text: https://secwatch.observer/filing/0000950170-25-068020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.